SEP 09, 2020 12:47 PM PDT

New Achondroplasia Treatment

WRITTEN BY: Nouran Amin

A recent clinical trial study found that an experimental drug, known as vosoritide, can be a potential treatment for achondroplasia (a common type of child dwarfism).

"This drug is like releasing the handbrake on a car, it lets you get up to full speed instead of having to drive with the brakes on,” says MCRI clinical geneticist Professor Ravi Savarirayan.

Achondroplasia results in the over activity of a protein FGFR3 that negatively impacts bone growth. Currently treatments involve surgical interventions in comparison—vosoritide can me potentially be a molecular therapy targeting the origins of the disease without invasiveness.

Professor Savarirayan said, "We know that beyond the cold hard facts and figures around growth rates and bone biology, we have hope that a treatment can improve kids' health outcomes, social functioning and increase access to their environments. Anecdotally, our patients tell us they now are able to do more stuff like climbing trees, jumping rocks and being more independent generally, which is specific to their experiences."

Learn more about Achondroplasia:

https://www.youtube.com/watch?v=gt-SAjuikLM

Findings were published in the medical journal, The Lancet and describes how Vosoritide works by blocking FGFR3 activity and returning bone growth to normal.

Dr. Johnathon Day, the Medical Director of Clinical Science at BioMarin Pharmaceutical Inc. notes, "Vosoritide is the first potential precision pharmacological therapy that addresses the underlying cause of achondroplasia and this randomized, double-blind, placebo-controlled Phase 3 study further adds to the scientific knowledge we've gained over many years from the clinical development program. I'd like to personally thank and congratulate all of the investigators and I am especially grateful to all of the children and their families who have participated in these studies.”

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
DEC 10, 2020
Immunology
Drug Turns Back the Clock in Aged Brains
DEC 10, 2020
Drug Turns Back the Clock in Aged Brains
When faced with stressful stimuli — anything from oxygen or nutrient deprivation to viral infections — cells ...
DEC 09, 2020
Drug Discovery & Development
Natural Sugar Alternative Stevia May Cause Gut Bacteria Imbalance
DEC 09, 2020
Natural Sugar Alternative Stevia May Cause Gut Bacteria Imbalance
Governments are keen to create regulations to reduce sugar intake. As such, companies are increasing their usage of arti ...
DEC 08, 2020
Drug Discovery & Development
Powerful Antibiotic Targets Mycobacterium
DEC 08, 2020
Powerful Antibiotic Targets Mycobacterium
Mycobacterium abscessus is a pathogenic bacterium know to cause tuberculosis and leprosy. Researchers at Johns Hopkins U ...
DEC 18, 2020
Drug Discovery & Development
Antibiotic Reduces Risk of Deafness
DEC 18, 2020
Antibiotic Reduces Risk of Deafness
Gentamicin is an antibiotic recently shown to reduce the risk of developing deafness according to a Stanford Medicine st ...
DEC 27, 2020
Genetics & Genomics
Delivering DNA- & RNA-Based Therapies in a New Way
DEC 27, 2020
Delivering DNA- & RNA-Based Therapies in a New Way
Gene therapy holds tremendous promise for its potential to cure genetic diseases. We've also recently seen how critical ...
DEC 25, 2020
Drug Discovery & Development
Class of Antibiotics May Target Resistant Bacteria
DEC 25, 2020
Class of Antibiotics May Target Resistant Bacteria
Researchers found a new class of antibiotics for combatting antimicrobial resistance (AMR). Learn more about antibiotic ...
Loading Comments...